Drug intelligence / Profile preview

ASKG193

Development stage: Preclinical
Lead developer: AskGene Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ASKG193 is a novel masked **CD19 T-cell engager** developed for the treatment of cancer. It features a masking technology designed to enhance safety by reducing off-target activation while maintaining potency against CD19-expressing tumor cells, enabling expanded therapeutic window for bispecific T-cell redirection therapies.[7]

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ASKG193.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKG193.

Explore the full profile